Dr. Michael S. Mcallister, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 878
Licensed in Alabama since 2001, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Alabama School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
AL license 24229 (first issued 2001; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Southeast Health Medical Center Dothan, AL
- Flowers Hospital Dothan, AL
Medical groups
- Dothan Hematology and Oncology, P. C. (15 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 878
- Services billed
- 254,954
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 44,450 | 13 |
| Injection, aprepitant, 1 mg | 31,070 | 65 |
| Injection, pembrolizumab, 1 mg | 22,400 | 26 |
| Injection, granisetron, extended-release, 0.1 mg | 20,500 | 56 |
| Injection, oxaliplatin, 0.5 mg | 18,200 | 13 |
| Injection, denosumab, 1 mg | 13,920 | 94 |
| Injection, paclitaxel, 1 mg | 7,240 | 13 |
| Injection, ondansetron hydrochloride, per 1 mg | 5,204 | 108 |
| Injection, dexamethasone sodium phosphate, 1 mg | 4,662 | 130 |
| Injection, eflapegrastim-xnst, 0.1 mg | 4,488 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Dothan, AL | 201 |
| Aprepitant | 139 |
| Anastrozole Other prescribers in Dothan, AL | 131 |
| Xtandi (enzalutamide) | 77 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Dothan, AL | 71 |
| Ibrance (palbociclib) | 58 |
| Prochlorperazine Maleate Other prescribers in Dothan, AL | 54 |
| Prednisone Other prescribers in Dothan, AL | 54 |
| Ondansetron Hcl Other prescribers in Dothan, AL | 53 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Dothan, AL | 47 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 41 companies reported 138 payments worth $21,954 in total to this clinician.
| Gilead Sciences, Inc. | $18,840 |
|---|---|
| Asd Specialty Healthcare, LLC | $314 |
| Daiichi Sankyo Inc. | $232 |
| Incyte Corporation | $230 |
| Genzyme Corporation | $212 |
| Beone Medicines USA, Inc. | $205 |
| Ipsen Biopharmaceuticals, Inc | $161 |
| Pfizer Inc. | $142 |
| Compensation for services other than consulting (speaking, faculty) | $15,170 |
|---|---|
| Food and Beverage | $3,888 |
| Travel and Lodging | $2,896 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) Trodelvy · ONC Company’s description;4023012;GTF;10426707 | $5,290 |
| Gilead Sciences, Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) Trodelvy · ONC Company’s description;4126911;AHM;10426707 | $4,940 |
| Gilead Sciences, Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Trodelvy · ONC Company’s description;4260223;AHM;10426707 | $4,940 |
| Gilead Sciences, Inc. Oct 31, 2025 | Travel and Lodging Trodelvy · ONC · travel to Mobile, AL · in-kind Company’s description;4328010;AHM;10426707 | $1,396 |
| Gilead Sciences, Inc. Feb 11, 2025 | Travel and Lodging Trodelvy · ONC · travel to Dallas, TX Company’s description;4022885;GTF;10426707 | $668 |
| Gilead Sciences, Inc. Jun 10, 2025 | Travel and Lodging Trodelvy · ONC · travel to Biloxi, MS · in-kind Company’s description;4098820;AHM;10426707 | $354 |
| Gilead Sciences, Inc. Feb 19, 2025 | Travel and Lodging Trodelvy · ONC · travel to Dallas, TX · in-kind Company’s description;4022656;GTF;10426707 | $293 |
| Gilead Sciences, Inc. May 15, 2025 | Travel and Lodging Trodelvy · ONC · travel to Biloxi, MS · in-kind Company’s description;4123437;AHM;10426707 | $167 |
| Gilead Sciences, Inc. Feb 22, 2025 | Travel and Lodging Trodelvy · ONC · travel to Dallas, TX Company’s description;4022932;GTF;10426707 | $18.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $149,755 in research payments for these studies, mostly to the institutions running them.
- CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase In…
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.